Drotrecogin Alfa (Activated) for Adults with Severe Sepsis and a Low Risk of Death
Edward Abraham(New York Medical College), William L. Macias(MDS Associates (United States)), Rolf Rossaint(Unknown), Martina Brückmann(University of Mannheim), Armin Sablotzki(Klinikum St. Georg), Deepak Talwar, Álvaro Réa-Neto, D. Perrotin(Université de Tours), Pierre‐François Laterre(Cliniques Universitaires Saint-Luc), Howard Levy(Apple (Israel)), Jeffrey S. Guy(Vanderbilt University Medical Center), Bruno François(Inserm), Rekha Garg(Therapeutics Clinical Research), Nancy Arkins(Eli Lilly (United States)), Barbara G. Utterback(Eli Lilly (United States)), Benjamin Trzaskoma(MDS Associates (United States))
Cited by 890
Related Papers
Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
|New England Journal of Medicine|2001|6.1k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Critical Care Medicine|2003|6k
2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
|Intensive Care Medicine|2003|2.9k